Zespri Revenue, Valuation, Funding & Investors

Zespri is valued at $1B as of February 2025, a 3.8x multiple on its last reported $268M revenue.

Last Zespri valuation

$1B

Series A · Feb 2025

Last Zespri funding round

$1M

Series A · Feb 2025

Zespri revenue

$268M

Series A · Feb 2025

Zespri Overview

About Zespri

Zespri is a New Zealand-headquartered marketer of kiwifruit, representing 3,300 growers exporting 180 million trays annually to 55 countries. The cooperative sells green, gold, organic, and SunGold varieties, generating over NZ$3 billion in revenue. Tauranga-based Zespri manages supply chain logistics, R&D for new cultivars like RubyRed, and sustainability programs including carbon-neutral goals by 2025. Key markets include China, Europe, and North America, with innovations in post-harvest technology extending shelf life.


HQ

ChinaShenzhen

Website

zespri.com

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Revenue

$268M (Feb 2025)

Valuation

$1B (Feb 2025)

Zespri Valuation

Zespri is currently valued at $1B, based on its Series A in February 2025.

Zespri valuation by funding round

Zespri valuation by funding round
DateStageValuationRevenue Multiple
Feb 2025Series A$1B3.8x

Zespri Revenue

Zespri's latest recorded revenue is $268M, as of its Series A in February 2025. At a $1B valuation, that implies a 3.8x revenue multiple.

Zespri revenue by funding round

Zespri revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Feb 2025$268M$1B3.8xSeries A

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Zespri Funding History

Zespri has raised a total of $1M across 1 funding round.

Zespri funding rounds

Zespri funding rounds
DateStageRaisedValuationDeal Summary
Feb 2025Series A$1M$1BZespri Group is a New Zealand-based kiwifruit grower cooperative that manages the production and commercialization of kiwifruit globally. The company operates licensing systems for producers across multiple kiwifruit varieties including Green, SunGold, Organic SunGold, and the premium RubyRed variant, and generates revenue through grower payments, licence fees, and export sales. In May 2025, independent investment bank Northington Partners valued Zespri's enterprise value at NZD 1,679–1,874 million on a cash/debt-free basis, with a corresponding estimated market value range of NZD 6.82–7.41 per share (or NZD 5.67–6.26 ex-dividend). This valuation supported a share buyback price of NZD 5.90 announced in July 2025. For the financial year ending June 2025, Zespri reported record revenue of NZD 440 million, up 7% from the prior year, and EBITDA of NZD 96 million, a 26% increase from NZD 76 million in FY2024. The company achieved a profit after tax of NZD 32 million in FY2025, representing a 265% increase from NZD 8.8 million in FY2024. The enterprise value to FY2025 EBIT multiple range implied by the valuation was 8.1x–9.0x. Strong global demand for kiwifruit, particularly in Europe and North America, drove Zespri's growth trajectory, with the company selling approximately 215 million trays in the 2025/26 season and forecasting record per-hectare returns across all fruit categories.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Zespri Competitors

Zespri competitors include listed companies like BioGaia, Procter & Gamble Health, Mega Lifesciences and PharmaNutra, and private ones like L&P Cosmetic and Pendulum Therapeutics.

Public and private companies comparable to Zespri
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
BioGaiaSwedenSwedenPublicly listed$157M$44M$1.1B6.2x
Procter & Gamble HealthIndiaIndiaPublicly listed$144M$48M$941M6.0x
Mega LifesciencesThailandThailandPublicly listed$425M$82M$936M1.9x
L&P CosmeticSouth KoreaSeoulPrivate--$1.1B-
PharmaNutraItalyItalyPublicly listed$153M$39M$851M5.0x
Pendulum TherapeuticsUnited StatesSan Francisco, CAPrivate$40M-$308M7.7x

Zespri Public Comps

Zespri is still privately-owned, but its public comps include BioGaia, Procter & Gamble Health, Mega Lifesciences, PharmaNutra, Aarti Pharmalabs, Tempo Scan Pacific, Genomma Lab, Jamieson Wellness, Biogena Good Vibes and Sido Muncul.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
BioGaia$157M$44M6.8x6.2x23.9x20.4x
Procter & Gamble Health$144M$48M6.4x6.0x19.1x18.3x
Mega Lifesciences$425M$82M2.0x1.9x10.2x8.4x
PharmaNutra$153M$39M5.6x5.0x22.0x19.3x
Aarti Pharmalabs$186M$40M4.6x-21.4x-
Tempo Scan Pacific$790M$111M0.6x-4.5x-
Genomma Lab$1B$203M1.0x1.0x5.0x4.2x
Jamieson Wellness$589M$95M2.9x2.6x17.8x13.5x

This data is available for Pro users. Sign up to see all Zespri competitors and their valuation data.

Start Free Trial

Common questions about Zespri

Where is Zespri headquartered?Zespri is headquartered in Shenzhen, China.
Is Zespri publicly listed?No, Zespri is a private company.
What is Zespri's valuation?Zespri was last valued at $1B in its Series A in February 2025.
How much funding has Zespri raised?Zespri has raised $1M across 1 funding round.
What was Zespri's last funding round?Zespri's last funding round was a $1M Series A in February 2025.
What is Zespri's revenue?Zespri's latest recorded revenue is $268M (February 2025).
What is Zespri's revenue multiple?Zespri's latest valuation implies a 3.8x revenue multiple ($1B valuation on $268M of revenue).
Which companies are comparable to Zespri?Companies comparable to Zespri include BioGaia, Procter & Gamble Health, Mega Lifesciences, L&P Cosmetic, PharmaNutra and Pendulum Therapeutics.

See companies similar to Zespri

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial